Table 3.

Multivariate Analysis (Cox proportional hazards regression) of Lymphoma Subtypes as Defined by the Kiel Classification1,2 in Relation to the Prognostic Factors or Risk Groups of the International Index12 

Overall SurvivalRelapse-Free
PRelative RiskSurvival
PRelative Risk
Comparison with risk factors 
Kiel classification 
CB/B-IB/B-ALC  .08  .025 
CB/B-IB  .036 1.78 .007 3.00 
CB/B-ALC  .15 1.65 .77 1.20 
Karnofsky index ≤ 70%  .0003 0.42 n.s. 0.79 
Age > 60 yrs  .06 1.56 .007 2.70 
Serum-LDH > normal  .036 1.81 n.s. 1.15 
Ann Arbor stage III/IV n.s. 1.44 n.s. 1.42 
No. of E-sites ≥ 2 n.s. 1.30 n.s. 1.63 
Comparison with risk categories 
Kiel classification 
CB/B-IB/B-ALC  .013  .023 
CB/B-IB  .006 2.09 .008 2.45 
CB/B-ALC  .06 1.84 .84 0.90 
Risk category low/high <.0001 2.49 .0004 2.81 
Overall SurvivalRelapse-Free
PRelative RiskSurvival
PRelative Risk
Comparison with risk factors 
Kiel classification 
CB/B-IB/B-ALC  .08  .025 
CB/B-IB  .036 1.78 .007 3.00 
CB/B-ALC  .15 1.65 .77 1.20 
Karnofsky index ≤ 70%  .0003 0.42 n.s. 0.79 
Age > 60 yrs  .06 1.56 .007 2.70 
Serum-LDH > normal  .036 1.81 n.s. 1.15 
Ann Arbor stage III/IV n.s. 1.44 n.s. 1.42 
No. of E-sites ≥ 2 n.s. 1.30 n.s. 1.63 
Comparison with risk categories 
Kiel classification 
CB/B-IB/B-ALC  .013  .023 
CB/B-IB  .006 2.09 .008 2.45 
CB/B-ALC  .06 1.84 .84 0.90 
Risk category low/high <.0001 2.49 .0004 2.81 

Abbreviation: n.s., not significant (P > .05).

Lymphoma subtypes: CB, centroblastic; B-IB, B-immunoblastic; B-ALC, B-anaplastic large cell (CD30+).

E-site, extranodal manifestation.

Risk category low: risk group low and low-intermediate12; high: risk group high-intermediate and high.12 

Close Modal

or Create an Account

Close Modal
Close Modal